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Membrane transporters are considered essential for placental amino
acid transfer, but the contribution of other factors, such as blood flow
and metabolism, is poorly defined. In this study we combine experi-
mental and modeling approaches to understand the determinants of
[14C]phenylalanine transfer across the isolated perfused human pla-
centa. Transfer of [14C]phenylalanine across the isolated perfused
human placenta was determined at different maternal and fetal flow
rates. Maternal flow rate was set at 10, 14, and 18 ml/min for 1 h each.
At each maternal flow rate, fetal flow rates were set at 3, 6, and 9
ml/min for 20 min each. Appearance of [14C]phenylalanine was
measured in the maternal and fetal venous exudates. Computational
modeling of phenylalanine transfer was undertaken to allow compar-
ison of the experimental data with predicted phenylalanine uptake and
transfer under different initial assumptions. Placental uptake (mol/min) of
[14C]phenylalanine increased with maternal, but not fetal, flow. Delivery
(mol/min) of [14C]phenylalanine to the fetal circulation was not associ-
ated with fetal or maternal flow. The absence of a relationship between
placental phenylalanine uptake and net flux of phenylalanine to the fetal
circulation suggests that factors other than flow or transporter-mediated
uptake are important determinants of phenylalanine transfer. These ob-
servations could be explained by tight regulation of free amino acid levels
within the placenta or properties of the facilitated transporters mediating
phenylalanine transport. We suggest that amino acid metabolism, primar-
ily incorporation into protein, is controlling free amino acid levels and,
thus, placental transfer.
blood flow; amino acid transfer; exchanger; facilitated transport;
metabolism
UNDERSTANDING THE DETERMINANTS of placental function and
fetal growth are important, as poor fetal growth is associated
with impaired health throughout life (14). Amino acid transfer,
a key placental function required for fetal growth, is reduced in
growth-restricted pregnancies (23). To understand why placen-
tal amino acid transfer becomes restricted in these pregnancies,
we need to define the factors that may be limiting to this
process. It is clear that net placental amino acid flux to the fetus
is dependent on membrane transport proteins localized to the
microvillous membrane (MVM) and basal plasma membrane
(BM) of the syncytiotrophoblast (9). However, other variables,
such as blood flow and metabolism, could be equally limiting
to net placental amino acid transfer (18).
In growth-restricted pregnancies, umbilical blood flow may
be reduced by 50%, impairing transfer of oxygen and, poten-
tially, other nutrients to the fetus (1). Substances predomi-
nantly transferred by diffusion, such as small hydrophobic
solutes, are most likely to be sensitive to flow, as their net flux
is driven by concentration gradients maintained by maternal
and fetal blood flows. Under these circumstances, maintenance
of a transplacental concentration gradient is a key determinant
of oxygen transfer by simple diffusion and glucose transfer by
facilitated diffusion (5, 10, 29). For substances predominantly
transferred by active transport (charged and/or hydrophilic
solutes), maternal blood flow is necessary to deliver substrates
for transfer to the transporting plasma membrane, but flow is
less likely to be the rate-limiting step, as transfer is not directly
dependent on transplacental concentration gradients.
Amino acid transfer across the placenta is an active process
that occurs against a concentration gradient (6, 9). As such,
placental amino acid transfer has not generally been considered
to be flow-limited. Nevertheless, many of the amino acid
transporters involved in this process do rely on transmembrane
concentration gradients (8, 22). In particular, transfer of amino
acids from the placenta to the fetal circulation, across the BM, is
mediated by facilitated transporters and exchangers, both of which
rely on transmembrane amino acid concentration gradients across
the plasma membrane for their activity (7, 8). With fetoplacental
blood flow determining amino acid concentrations in the fetal
capillaries, the issue of flow dependency of amino acid transfer
from the placenta to the fetus is raised in the context of presiding
concentration gradients across the BM. As amino acid concentra-
tions are believed to be much higher within placental tissue than
in fetal capillaries, any change in transmembrane concentration
gradient due to flow is likely to be relatively small (24). Hence,
the effect of fetal flow on transfer would be predicted to be small
but requires experimental validation.
Flow-limited transfer has been studied previously in the
isolated perfused human placenta and has been clearly estab-
lished, as expected, for antipyrine (28). There is also evidence
that maternal flow rate affects transfer of glucose across the
isolated perfused human placenta (15). Modeling of placental
amino acid transfer also suggests that flow may be an important
determinant (18). Phenylalanine is a good candidate amino
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acid with which to study possible flow effects, as it is trans-
ported by exchangers [SLC7A5 (LAT1) and/or SLC7A8
(LAT2)] and facilitated transporters [SLC16A10 (TAT1),
SLC43A1 (LAT3), and SLC43A2 (LAT4)], the activity of
which is dependent on concentration gradients that are sensi-
tive to flow (8, 22). Phenylalanine, taken up by the placenta,
may be incorporated into protein; however, as there is little or
no phenylalanine hydroxylase in the human placenta, loss via
catabolism is likely to be limited (20). Using experimental and
modeling approaches, we set out to investigate whether factors
such as maternal and fetal blood flow influence placental
transfer of the amino acid phenylalanine as a model for
essential amino acid transport by exchangers and facilitated
transporters across the human placenta.
METHODS
Human placentas were collected from daytime full-term vaginal
deliveries from uncomplicated pregnancies at the Princess Anne
Hospital in Southampton, in accordance with ethical approval from
the Southampton and Southwest Hampshire Regional Ethics Commit-
tee (approval no. 11/sc/0323).
Perfusion methodology. Placentas were perfused using the meth-
odology of Schneider et al. (28), as adapted in our laboratory (10, 11).
Placentas were collected within 30 min of delivery and placed on ice
for transport to the laboratory, where fetal-side perfusion was estab-
lished within 30 min of collection. The fetal and maternal circulations
were perfused at 6 and 14 ml/min, respectively, with Earle’s bicarbonate
buffer (EBB; in mM: 1.8 CaCl2, 0.4 MgSO4, 116.4 NaCl, 5.4 KCl, 26.2
NaHCO3, 0.9 NaH2PO4, and 5.5 glucose) containing 0.1% (wt/vol)
bovine serum albumin and 5,000 IU/l heparin and equilibrated with 95%
O2-5% CO2. Perfusion of the fetal circulation was established, and, if
fetal venous outflow was 95% of fetal arterial inflow, maternal arteri-
alerfusion was established 15 min later. Maternal arterial catheters are
placed through the maternal decidual surface of the placenta and into the
intervillous space. The maternal venous outflows are not catheterized, but
maternal venous exudate appearing on the surface of the cotyledon was
channeled to a collection point.
Phenylalanine experiment methodology. Phenylalanine was chosen
as the candidate amino acid, as it is a substrate for both exchangers
and facilitated transporters (8). It is also not catabolized (i.e., phenyl-
alanine hydroxylase is not expressed) within the human placenta (20).
Tracer concentrations of phenylalanine were used to study flow in an
experimental design where transporters were not saturated to ensure
that any effects of flow were apparent. Glutamate and taurine were
added to support metabolic and tissue homeostasis within the perfused
placental tissue (11, 12). The maternal circulation was perfused with
EBB containing 2.7 nmol/l [14C]phenylalanine [50 Ci (1.85 Mbq),
NEC284E050UC], 50 mol/l glutamate, and 50 mol/l taurine, along
with 1.8 mmol/l creatinine as a marker of paracellular diffusion. Initial
baseline maternal and fetal flow rates were 14 and 6 ml/min, respec-
tively, for 30 min. As outlined in Fig. 1, maternal flow rate was then
changed from 14 ml/min to 10 ml/min back to 14 ml/min and then to
18 ml/min for 1 h each. During each 1-h period, fetal flow rates were
ramped to 3, 6, and 9 ml/min for 20 min each. In each 20-min block,
maternal and fetal venous exudates were sampled at 5, 10, 15, and 18
min. Finally, the tissue was washed by perfusion of both circulations
for 15 min with buffer that did not contain [14C]phenylalanine. After
the perfusion protocol, the cotyledon was trimmed of nonperfused
areas (perfused areas become blanched), and the cotyledon was frozen
for analysis of intracellular amino acids.
Placental uptake (mol/min) was calculated from the difference in
concentration (mol/l) between maternal arterial and maternal venous
outflow, multiplied by maternal flow rate (l/min). Placental transfer
(mol/min) was calculated from fetal vein concentrations (mol/l) mul-
tiplied by fetal flow rate (l/min).





















Fig. 1. Experimental design and modeling schematic. A: experimental design. Step-
wise changes in maternal and fetal perfusion flow rates from the beginning of
[14C]phenylalanine tracer infusion. After an initial 20-min equilibration period, flow
rates were varied every 20 min and maternal and fetal venous outflow samples were
collected at 15 and 18 min to determine uptake and transfer, respectively. B: conceptual
outline of phenylalanine transport across the human placenta showing the classes of
transporters involved on the microvillous (MVM) and basal (BM) plasma membranes
of the placental syncytiotrophoblast, as well as incorporation into the protein pool
(catabolism is not shown, as phenylalanine hydroxylase is not expressed in the
placenta). C: compartmental computational modeling of transporter-mediated phenyl-
alanine transfer. F is flow in maternal or fetal arteries, [Phe] is [14C]phenylalanine
concentration in the respective compartments of the maternal intervillous space (m),
syncytiotrophoblast (s), and fetal capillaries (f), and v is compartment volume. J
represents net flux between compartments for exchangers (ex) or facilitated transport-
ers (fa), and metabolism is given by Jmetab. While it was assumed that metabolism of
phenylalanine was predominantly protein synthesis, which is reversible, given the short
experimental time frame, flux of [14C]phenylalanine back from protein to the free
amino acid pool was not modeled (dashed arrow). Phenylalanine uptake in the placenta
via exchange is driven by high intracellular concentrations of endogenous substrates of
the facilitated and exchange (fa and ex) or exchange-only (ex) transporters.
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Tissue amino acid measurements. To study intracellular [14C]phe-
nylalanine, the cotyledons were homogenized in three volumes of
distilled water and centrifuged at 10,000 g for 10 min to remove
cellular debris. A 1-ml sample of homogenate was mixed with an
equal volume of 10% trichloroacetic acid to precipitate protein. The
pellet and supernatant were counted separately in a liquid scintillation
counter (Tri-Carb 2100TR, Perkin Elmer Life Sciences) on standard
counting windows for 14C to determine [14C]phenylalanine incorporated
into protein and free 14C tracer. To assess potential quenching of radio-
active counts by tissue components, the supernatant and protein pellet
were prepared as described above, and serial double dilutions were
performed, with each sample being spiked with a standard amount of 14C
tracer and counted as described above. No quenching was observed in the
supernatant, but within the protein pellet, efficiency of counting was 31%,
and these counts were adjusted accordingly.
Computational modeling. A compartmental model to represent the
intervillous space, syncytiotrophoblast, and fetal capillaries was con-
structed using relative volume fractions from the literature (30). Flow
rates were based on the experimental protocol outlined in Fig. 1, and
overall cotyledon volume was based on the average value from these
experiments (with the assumption of 1 ml/g tissue). The placenta was
modeled with generic exchange and facilitated transporters as outlined
in Fig. 1, B and C. Model equations were implemented in MATLAB
(R2014b) as outlined previously (22, 30).
Transport modeling. A carrier-based model was used to represent
the transporters, as outlined previously (22, 32). Net flux JAI¡II
(mol/min) of substrate A from compartment I to compartment II for
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for the facilitated transporter (fa). [A]I is the concentration (mol/l) of
substrate A in compartment I and [Tot]I is the total sum of all
substrates of the exchanger or the facilitative transporter in compartment
I, while [R]exI is the sum of all exchanger substrates, excluding substrate
A. K is the dissociation constant (mol/l) for the exchanger (Kex) or
facilitated transporter (Kfa), and the maximum transport rate (Vmax,
mol/min) is Vex for the exchanger or Vfa for the facilitated transporter.
Intracellular amino acids were represented by two generic amino
acids, to differentiate between substrates of the transporters that
transport phenylalanine by both exchange and facilitated transporters
and substrates transported by exchange transporters only. For the first
generic amino acid, i.e., substrates transported by facilitated trans-
porters [SLC16A10 (TAT1), SLC43A1 (LAT3), and SLC43A2
(LAT4)] and exchangers [SLC7A5 (LAT1) and SCL7A8 (LAT2)],
which includes phenylalanine (alanine, isoleucine, leucine, methio-
nine, phenylalanine, tyrosine, tryptophan, and valine), the sum of the
intracellular concentrations available in the literature for these amino
acids, 3,132 mol/l, was applied (19, 24). For the second generic
amino acid, the sum of those intracellular concentrations available in
the literature for amino acids transported by exchangers (but not
facilitated transporters), including phenylalanine (asparagine, cys-
teine, glutamine, glycine, histidine, serine, and threonine), 4,491
mol/l, was applied. Previous data indicate few instances of signifi-
cant decline in intracellular amino acid concentrations in perfused
human placentas provided with glutamate over the course of an
experiment (11). As such, the intracellular concentrations of the two
generic amino acids within the model were kept constant throughout
the experiment.
MVM and BM exchangers were assumed to be symmetrical, with
the same dissociation constants on either side of the membrane in
MVM and BM (Kex  200 mol/l and Kfa  1,000 mol/l) (22). At
steady state, net transfer in the model will be the same whether or not
transporters are symmetrical. While it remains to be established how
this affects the system for different operating conditions, we did not
want to introduce additional model parameters without experimental
justification. Vmax values were fitted by manual adjustment of the
parameters, so that the model matched the average of the experimental
steady-state placental uptake and transfer values over all flow condi-
tions. In the first instance, the BM exchanger and facilitated trans-
porter were assumed to have the same Vmax to reduce the number of
parameters required for the model. For uptake under physiological
amino acid concentrations, we represented maternal input amino acid
concentrations with the approaches of the two generic amino acids
described above using literature values (19). With maternal values for
the facilitated substrates, this value was 615 mol/l, and for the
exchanger-only substrates, this value was 915 mol/l.
Flow modeling. Blood flow into and out of the maternal and fetal
compartments results in a net molecular flux JA,flowi (mol/min) as
follows
JA,flow
i  FiAini  Ai
where [A]ini is the inlet concentration (mol/l) of substrate A in
compartment i and [A]i is the concentration of substrate A in com-
partment i. Fi is the constant flow rate into and out of compartment i
(l/min).
Metabolic modeling. Metabolism of amino acids was represented
by linear kinetics with the assumption of an unsaturated process with
rate constant kmetab. The rate constant was determined simultaneously
by fitting average steady-state amino acid uptake and transfer
JA,metab
S  KmetabAs
where JA,metabs is the metabolic rate (mol/min), [A]s is the concentra-
tion (mol/l) of substrate A in the syncytiotrophoblast, and kmetab is the
rate constant (l/min). This equation represents all metabolic removal
of phenylalanine, and as there is no phenylalanine hydroxylase activ-
ity, this equation is likely to represent primarily protein synthesis
incorporation. The release of amino acids from the protein pool was
not modeled, as median protein half-lives are considerably longer than
the course of this experiment (25).
Diffusion modeling. To determine if diffusion could explain the
transfer of phenylalanine, the effective diffusive permeability was
fitted by manual adjustment of this parameter, so that the model
matched the experimental average steady-state placental uptake.




where Vdif is the effective diffusive permeability constant (l/min).
Compartmental modeling. A compartmental modeling approach
was adopted on the basis of our previous work (30), in which the
placenta was represented as three separate volumes corresponding to
the maternal intervillous space, syncytiotrophoblast, and fetal capil-
laries. All compartments were assumed to be well mixed. The transfer
of amino acids between the compartments was modeled as fluxes
mediated by the exchange transporters at the MVM and facilitative
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where [A]i is the concentration (mol/l) of substrate A in compartment
i and vi is the volume of compartment i (liters). JA,xi¡j represents the net
molecular flux (mol/min) of substrate A from compartment i to
compartment j mediated by transporter x. Here m, s, and f represent
the maternal, syncytiotrophoblast, and fetal compartments, respec-
tively, while ac, ex, and fa denote the accumulative, exchange, and
facilitative transporters, respectively. JA,flowi is the net molecular flux
of substrate A due to blood flow, JA,metabs is the consumption of
substrate A by metabolic processes (for phenylalanine, primarily
protein synthesis), and JA,difm¡f is flux due to paracellular diffusion.
Model equations were implemented in MATLAB (R2014b). Simula-
tions were carried out for transporters alone or for diffusive transfer
alone by omission of the relevant terms in the compartmental model
equations.
Parameter variation was undertaken in the final transport model to
mimic metabolism by modeling the effect of a fivefold increase and
decrease in model parameters on uptake or transfer of phenylalanine.
Statistics
Data were analyzed by two-way ANOVA, with maternal and fetal
flow as discrete variables. Linear regression analysis was performed to
compare experimental data with model predictions. Values are means 
SE; n is the number of placentas.
RESULTS
Perfusion data. The average cotyledon weight was 42.0 
9.7 g (n  5 placentas) and maternal flow rates were 10, 14,
and 18 ml/min; these values equate to maternal flow rates of
0.31  0.08, 0.43  0.11, and 0.55  0.14 ml/g placental
cotyledon. For fetal flow rates of 3, 6, and 9 ml/min, these
values equate to fetal flow rates of 0.09  0.02, 0.18  0.05,
and 0.28  0.07 ml/g placental cotyledon. Average fetal
perfusate recovery was 5.88  0.06 ml/min at the beginning
and 5.76  0.09 ml/min at the end (at 6 ml/min flow rate) of
the experiment. Average maternal recovery was 13.92  0.08
ml/min at the beginning and 13.92 0.08 ml/min at the end (at
14 ml/min flow rate) of the experiment.
Placental uptake of [14C]phenylalanine. Placental uptake of
[14C]phenylalanine increased with increasing maternal flow
(n  5 placentas, P  0.011) but was not related to fetal flow
(Fig. 2A). There were no significant interactions between
maternal and fetal flow. The computational model was used to
predict placental uptake, with the assumption of simple diffusion
(Fig. 2B) and transport (MVM exchange and BM-facilitated
transport and exchange; Fig. 2C). The experimental data were
most consistent with uptake by transport (R2  0.77), rather than
simple diffusion (R2  0.02). The simulation was also conducted
in the presence of physiological maternal concentrations of amino





















































































































































































































































D Fig. 2. Placental phenylalanine uptake from maternal circulation: experimental
data and predicted transfer under certain assumptions. 10M, 14M, and 18M,
maternal flow of 10, 14, and 18 ml/min; 3F, 6F, and 9F, fetal flow of 3, 6, and
9 ml/min. A: experimental uptake of [14C]phenylalanine across the perfused
placental lobule. Uptake of [14C]phenylalanine from the maternal circulation
was associated with maternal (P  0.011), but not fetal (P  0.41), flow rates.
There were no significant interactions between maternal and fetal flow (P 
0.96). Values are means  SE; n  5 placentas. B: predicted uptake of
phenylalanine if transfer is mediated by simple diffusion. Maternal uptake
levels could not be matched, and there was no correlation between predicted
uptake and experimental data (R2  0.02). C: predicted uptake of phenylala-
nine if transfer is mediated by facilitated and exchange transporters. There was
good correlation between predicted uptake and experimental data (R2  0.77).
D: predicted uptake of phenylalanine tracer at physiological maternal arterial
amino acid levels if transfer is mediated by transporters and with the assump-
tion of intracellular metabolism or compartmentalization. Because amino acid
(aa) concentrations within the perfusate are much higher, delivery is no longer
rate-limiting and maternal flow does not determine uptake.
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phenylalanine uptake (Fig. 2D). Predicted uptake was essentially
identical if modeled with or without placental metabolism; there-
fore, in Fig. 2, C and D, the predictions show uptake for the model
that included metabolism, to match Fig. 3D.
Placental transfer of [14C]phenylalanine. Net flux of
[14C]phenylalanine (mol/min) to the fetus was unaffected by
varying fetal (P  0.89) or maternal (P  0.94) flow rates, nor
was there an interaction between maternal and fetal flow (P 
0.95, n  5; Fig. 3A). As such, the increase in placental uptake
with increasing maternal flow did not translate into an in-
creased transfer to the fetal circulation. The computational
model was used to predict placental transfer with the assump-
tion of simple diffusion (Fig. 3B) and transport (MVM ex-
change and BM-facilitated transport and exchange), first, in the
absence of metabolism or compartmentalization (Fig. 3C) and,
second, with the assumption of metabolism and/or compart-
mentalization (Fig. 3D). The second model, with the assump-
tion of syncytiotrophoblast metabolism and/or compartmental-
ization, provided the best overall representation of the exper-
imental data, as observed in Fig. 3D. Nonetheless, there was
still a progressive increase in phenylalanine transfer associated
with increasing maternal flow, although the fit was less con-
vincing than that for uptake (R2  0.12). The model could be
effectively fitted to the experimental data only if intracellular
phenylalanine concentration was kept constant within the syn-
cytiotrophoblast.
Baseline uptake and transfer over time. [14C]phenylalanine
uptake and transfer were compared at baseline maternal and
fetal flow rates (14 and 6 ml/min, respectively) at the begin-
ning, middle, and end of the experiment. At baseline flow rates,
there were no differences in maternal venous concentration
(mol/l) or placental uptake (mol/min) over the course of the
experiment.
Creatinine transfer. Creatinine transfer was significantly
related to fetal (P  0.015), but not maternal, flow rate, and
there was no interaction between fetal and maternal flow rate
(n  5 placentas; Fig. 4).
Sensitivity analysis for the transport model, including
metabolism. Parameter variation was undertaken in the trans-
port model with metabolism included, in which the effect of a
fivefold increase and decrease in model parameter on the
uptake/transfer of phenylalanine was considered. The sensitiv-
ity analysis for uptake indicated that Vmax and K for the
exchanger on the MVM are the major determinants of transfer
(Fig. 5). The sensitivity analysis for transfer indicated that the

























































































































































































































































Fig. 3. Placental phenylalanine transfer: experimental data and predicted
transfer under certain assumptions. A: experimental transfer of [14C]phenyla-
lanine across the perfused placental lobule. Transfer of phenylalanine to the
fetal circulation was not related to maternal (P 0.89) or fetal (P 0.94) flow
rates, and there were no interactions between maternal and fetal flow (P 
0.95). Values are means  SE; n  5 placentas. B: predicted transfer of
phenylalanine if transfer is mediated by simple diffusion. Uptake and transfer
are equal, and fetal flow has the predominant effect on transfer. C: predicted
transfer of phenylalanine if transfer is mediated by transporters and with
the assumption of no intracellular metabolism or compartmentalization. Be-
cause uptake is greater than transfer, intracellular phenylalanine concentrations
rise over time, driving a progressive increase in transfer over the course of the
experiment. This scenario does not reflect the experimental data. D: predicted
transfer of phenylalanine if transfer is mediated by transporters and with the
assumption of intracellular metabolism or compartmentalization. While trans-
port with metabolism demonstrates the closest agreement with the experimen-
tal data (R2  0.14), none of the model outputs showed good correlation,
indicating that other factors are required to fully account for the mechanisms
underlying transfer of phenylalanine.
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of the exchanger on the MVM are major determinants of
transfer when metabolic rate is applied as a major limiting
factor. Sensitivity analysis showed that uptake under experi-
mental conditions was dependent on the ratio of K to Vmax in
the linear regimen (Fig. 5A). In the case of the BM, transfer
was highly sensitive to the rate of metabolism and Vmax of the
facilitated transporter (Fig. 5B). However, when sensitivity
analysis, including physiological amino acid concentrations,
was performed, distinct differences were observed, particularly
in regard to uptake, where metabolism and, to a lesser degree,
facilitated transporter Vmax now affected the model (Fig. 5, C
and D).
Tissue and protein counts and mass balance. On the basis of
the steady-state measurements over the course of the experi-
ment, [14C]phenylalanine uptake per cotyledon was 4.6  0.7
nmol, 15%, 0.7  0.02 nmol, of which was transferred to the
fetal circulation, leaving 3.9  0.01 nmol retained within the
perfused cotyledon (n  5 placentas). After protein precipita-
tion, 14C label was measured in the supernatant and in the
protein pellet derived from the perfused cotyledon. The con-
centration of free [14C]phenylalanine in the tissue was 1.0 
0.7 nmol/cotyledon and the amount of [14C]phenylalanine
incorporated into protein was 1.2  0.5 nmol/cotyledon. Total
recovery of [14C]phenylalanine was 2.2  0.8 nmol/cotyledon,
which equates to 56% of the tracer retained in the tissue (n 
5 placentas).
Estimation of [14C]phenylalanine gradient across the BM.
On the basis of a tissue [14C]phenylalanine content of 1.03
nmol/cotyledon, with a mean wet weight of 42 g, and the



















































Fig. 4. Creatinine transfer across the perfused human placenta. Creatinine
transfer was not significantly related to maternal flow rate (P 0.84), but there
was a significant relationship with fetal flow rate (P  0.015). There was no
interaction between maternal and fetal flows (P  0.94). Values are means 
SE; n  5 placentas.
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Fig. 5. Parameter variation showing the predicted effect of a 5-fold increase and decrease, respectively, in model parameters on uptake and transfer of
phenylalanine for the experimental paradigm (A and B) and modeled with physiological amino acid concentration (C and D). Lines for basal plasma membrane
(BM)-facilitated Vmax and Kfa are obscured by BM exchanger Vmax. A: sensitivity analysis for placental uptake indicates that placental uptake is dependent on
the ratio of K to Vmax in the linear transport regimen. B: sensitivity analysis for placental transfer indicates that placental transfer is highly sensitive to metabolic
rate and Vmax of the BM-facilitated transporter. This sensitivity analysis is based on the low uterine arterial phenylalanine concentration used in the experimental
model. Parameter variation shows the predicted effect of a 5-fold increase and decrease, respectively, in model parameter on uptake or transfer of phenylalanine
under conditions assumed for physiological modeling. C: sensitivity analysis for placental uptake under conditions assumed for physiological modeling indicates
that placental uptake is dependent on MVM exchanger Vmax and metabolic rate. There is a marked difference between predicted sensitivities under experimental
and physiological conditions. D: sensitivity analysis for placental transfer under conditions assumed for physiological modeling indicates that placental transfer
is sensitive to metabolic rate and Vmax of the MVM and BM-facilitated transporters.
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volume (21), the placental [14C]phenylalanine concentration
was calculated to be 163 nmol/l vs. fetal vein concentrations
of 1 nmol/l at low flow rates and 0.3 nmol/l at high flow rates.
DISCUSSION
This study demonstrates that factors additional to transporter
activity and flow determine placental transfer of phenylalanine
to the fetal circulation. Understanding the key determinants of
amino acid transfer is essential if we are to identify the
underlying causes of impaired amino acid transfer associated
with fetal growth restriction and mechanistic targets for poten-
tial interventions. The observation that increased placental
uptake of phenylalanine did not lead to corresponding in-
creases in transfer to the fetal circulation suggests that other
factors, such as incorporation into protein, are potentially
rate-limiting. This has important implications for our under-
standing of the regulation of amino acid transfer in the human
placenta.
The experiments performed here allowed investigation of
the dependence of placental uptake of phenylalanine from the
maternal circulation and transfer to the fetal circulation across
intact placental tissue on flow and the application of compu-
tational modeling to interpret the transfer mechanisms that
underlie these processes. The observation that phenylalanine
uptake was limited by maternal flow was consistent with
modeling predictions and illustrates that, at the concentration
of [14C]phenylalanine used in these experiments (2.7 pmol/l),
supply was inadequate to saturate transport capacity. However,
at physiological concentrations of amino acids (40 mol/l for
phenylalanine), supply is unlikely to become limiting; while
this needs to be demonstrated experimentally, the model im-
plies that phenylalanine uptake would not be flow-limited at
physiological concentrations. The demonstration that the ex-
perimental uptake data matched the transport model, rather
than the diffusion model, illustrates the role of transporters and
confirms that phenylalanine transfer in the perfusion system is
occurring by predicted mechanisms. The pattern of uptake
could not be fitted by the diffusion model, which showed a
strong effect of fetal flow that was not observed in the exper-
imental data.
We initially proposed that phenylalanine transfer could be
flow-limited on the BM, with its transfer across the BM of the
placental syncytiotrophoblast mediated by facilitated diffusion
(8). However, phenylalanine transfer occurred at a near-con-
stant rate across the range of fetal flow rates. This is consistent
with a high intracellular concentration within placental tissue
relative to the capillary concentration, as, in this case, changes
in fetal flow will have a relatively small effect on the overall
gradient and transfer. However, the transmembrane gradient
should have increased during the experiment both in response
to changes in [14C]phenylalanine uptake with increasing flow
and because uptake exceeded efflux. Although phenylalanine
uptake was 40% greater at the fastest than at the slowest
maternal flow rate, this did not translate into increased transfer
to the fetal circulation. Moreover, as illustrated by computa-
tional modeling, the observation that phenylalanine uptake was
greater than efflux implies that intracellular phenylalanine
concentration should have been increasing with time, driving
increased transfer to the fetal circulation (Fig. 3C). Explana-
tions for this discrepancy between uptake and transfer include
the following: 1) the intracellular concentration of free
[14C]phenylalanine, available for transfer, is controlled by
another factor, such as metabolism, or 2) the activity of the
facilitated transporters on the BM is not primarily determined
by the transmembrane concentration gradient.
BM-facilitated transport might not be determined by the
transmembrane concentration gradient for the following rea-
sons. First, BM-facilitated transport was saturated; however,
this is unlikely, as tracer concentration is well below the Km,
and, in this range, flux should increase proportionally with
concentration (even if transfer of the unlabeled substrate were
saturated). Second, facilitated amino acid transporters do not
operate as we would expect on the basis of observations of
other facilitated transporters such as GLUT1 (SLC2A1). Fa-
cilitated transport of glucose by GLUT1 (SLC2A1) appears to
be dependent on the transplacental concentration gradient, and
it seems reasonable to assume that facilitated amino acid
transporters may share this characteristic (10, 29). However,
the facilitated transporters LAT3 and LAT4 are reported to
have complex kinetics with multiple apparent affinities for
phenylalanine (3). It is therefore possible that they do not
operate in a manner consistent with previous observations for
other facilitated transporters. Further characterization of these
transporters is therefore warranted to help clarify this issue.
It is noteworthy that up to two-thirds of the [14C]phenyla-
lanine retained within the placenta was incorporated into pro-
tein. If this phenomenon applies to other amino acids, this
would reduce the intracellular concentration of amino acids
and, therefore, the amino acid concentration gradient driving
transfer to the fetus. Previous work in the guinea pig has
suggested an important role for protein metabolism in amino
acid transfer (4). Alternatively, phenylalanine catabolism or
sequestration within intracellular organelles could regulate the
free amino acid pool available for transport. When metabolism
was included in the model, the predicted transfer to the fetus
was much closer to the observed experimental data. Neverthe-
less, if we assume linear kinetics for metabolism, the model
could not fully reproduce the constant rate of phenylalanine
transfer observed experimentally. The reason for this is that, in
the model, increased maternal uptake would directly lead to a
higher equilibrium of intracellular amino acid concentration,
increasing the concentration gradients that drive amino acid
transport across the BM. Only if intracellular phenylalanine
concentration was fixed could the model provide a good
representation of our experimental data. Therefore, for metab-
olism to fully explain the data, regulation of metabolism would
be needed to maintain a constant free intracellular phenylala-
nine concentration at the BM interface.
A relatively high proportion of 14C label was unaccounted
for; this has been reported previously, but the cause for this
remains elusive (26). Catabolism is a possibility, but as phe-
nylalanine hydrolase is not expressed in the placenta, we
consider this unlikely (25). It is possible that phenylalanine
uptake may have been overestimated, as our calculations were
based on steady-state values, which may not fully reflect
equilibration time following changes in flow rate. Another
possibility is that the observed quenching in protein extracts
was not fully accounted for. In both cases, the proportion of
[14C]phenylalanine incorporated into protein would have been
underestimated, affecting estimates of tracer recovery.
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The observation that much of the [14C]phenylalanine taken
up was incorporated into protein suggests that metabolism and
integration of phenylalanine into protein make a significant
contribution. However, whether metabolism can fully explain
the discrepancy between the model and experimental data or
whether there is a combination of metabolism and some other
factor, such as compartmentalization or facilitated transporter
function, remains to be determined. For example, compartmen-
talization of the amino acid arginine has been proposed as an
explanation of the arginine paradox in nitric oxide production
(13). Protein synthesis inhibitors have been shown to be
effective in inhibition of protein synthesis in the perfused
placenta, and it would be interesting to determine if protein
synthesis inhibitors also stimulated the transfer of amino acids
to the fetus (2).
While all the factors modeled are necessary for transfer, it is
important to identify those that are most likely to become
rate-limiting and, thus, have the greatest clinical relevance. The
model sensitivity analysis identifies those factors that, if we
assume that the model is correct, have the greatest impact on
phenylalanine transfer. It is important to note that the sensitiv-
ity analysis favored different factors under experimental (low
phenylalanine concentrations) and physiological amino acid
concentrations. However, it appears that MVM exchanger
activity, BM-facilitated transporter activity, and incorporation
of amino acids into protein were predicted to be the primary
determinants of placental transfer.
As the experiments themselves were not performed with
physiological concentrations of amino acids, we should be
careful about extrapolating our findings to the physiological
situation. However, while experimental validation is required,
we are confident that the modeling framework is capable of
effectively representing the main transport processes relevant
for physiological fluids such as serum. We should also note
that the placenta is a more complex tissue than the model
currently reflects and that processes such as metabolism may
occur in cell types other than the syncytiotrophoblast.
In the normal placenta, maternal and fetal flow rates are on
the order of 2 and 0.2 ml·g placenta1·min1, respectively
(17). In this study our maternal flow rates were below normal
(15–30% of physiological), while our fetal flow rates spanned
the normal range (50–140% of physiological). Maternal blood
flows in this range or fetal flow of 50% would normally be
associated with placental disease, leading to preeclampsia or
fetal growth restriction (16).
This model is based on human full-term placenta but could
be applied to other gestational ages and species. By substitu-
tion of the data on the volumes of the different tissue compart-
ments, rates of uterine and umbilical blood flow, and the
localization of transporters, the basic model would be applica-
ble to a range of species or gestational ages.
Creatinine transfer across the human placenta is generally
believed to occur via paracellular diffusion (31), and, consis-
tent with this notion, the experimental data followed the pattern
predicted by the diffusion model, providing confidence in our
modeling approaches.
The perfusion system provides an excellent model for study
of placental transfer (27). Nevertheless, there are issues that
should be considered when the data are interpreted. First,
maternal-side perfusion may not fully represent the uteropla-
cental perfusion that occurs in vivo via the spiral arteries (26).
This may affect the efficiency of mixing within the intervillous
space and, thus, the efficiency of transfer. Second, this study
measured the transfer of one amino acid in the absence of other
amino acids that would normally be present. Amino acid
transfer is likely to be determined by interaction between
amino acids, and future studies including all amino acids
would be informative (18).
In considering these observations, we also need to be mind-
ful of the time course of these experiments, as the factors
limiting transfer over the course of 3 h may be different from
those limiting transfer over days, weeks, and longer. While
incorporation of phenylalanine into the protein pool and me-
tabolism may predominate over short time frames, in the
longer term, transport may affect amino acid availability for
protein synthesis, the size of the protein pool, and, thus,
transfer over extended periods. It is likely that protein synthesis
and breakdown are in quasi-steady state, with input and output
matched over time. This would allow the placenta to maintain
supply to the fetus in response to short-term variations in
maternal supply. If a significant proportion of placental amino
acids enters a protein pool before being transported to the fetus,
we may need to rethink the time frames over which amino acid
transfer is regulated.
In fetal growth-restricted pregnancies, many placental fac-
tors have been shown to be altered; some of these will be key
determinants of placental function, while others will not. A key
aim of the model is to be able to identify the factors that are
most likely to be rate-determining for placental transfer. These
factors are the most likely to become rate-limiting in fetal
growth-restricted pregnancies and need to be targeted for
successful interventions. By modeling the phenotypes ob-
served in fetal growth restriction, we hope to identify the
factors that are having the greatest effect on placental function
and, thus, fetal growth, as these are the most important targets
for future research.
In conclusion, this study suggests that transporter activity is
a major determinant of phenylalanine transfer across the per-
fused human placenta, but flow is not. However, our combined
experimental and computational modeling approach leads us to
conclude that other factors, such as metabolism and integration
into protein within the placenta, play a previously underappre-
ciated role.
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